adenosine monophosphate has been researched along with ST Elevation Myocardial Infarction in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 9 (56.25) | 2.80 |
| Authors | Studies |
|---|---|
| Gargiulo, G; Landi, A; Valgimigli, M | 1 |
| Angiolillo, DJ; Franchi, F; Rollini, F | 1 |
| Alexopoulos, D; Lianos, I; Mpahara, A; Varlamos, C | 1 |
| Avvedimento, M; Billinger, M; Campo, G; Cirillo, P; Esposito, G; Gargiulo, G; Gragnano, F; Heg, D; Hunziker, L; Manavifar, N; Minuz, P; Nagler, M; Piccolo, R; Tebaldi, M; Valgimigli, M; Wahl, A; Windecker, S | 1 |
| Buono, A; De Blasio, G; Ielasi, A; Loffi, M; Tespili, M | 1 |
| Abdel-Latif, A; Abo-Aly, M; Chelvarajan, L; El-Helw, M; George, B; Shokri, E; Smyth, SS; Ziada, K | 1 |
| Agostini, C; Bernardo, P; Caniato, F; Cappelli, F; Di Filippo, C; Di Mario, C; Mattesini, A; Meucci, F; Sori, A; Stolcova, M | 1 |
| Angiolillo, DJ; Bhatt, DL; Stone, GW | 1 |
| Gargiulo, G; Nagler, M; Valgimigli, M | 1 |
| Ben-Dor, I; Bernardo, NL; Case, BC; Chezar-Azerrad, C; Forrestal, BJ; Garcia-Garcia, HM; Hashim, H; Medranda, GA; Satler, LF; Shea, C; Waksman, R; Yerasi, C; Zhang, C | 1 |
| Alexopoulos, D; Didagelos, M; Iliodromitis, E; Karvounis, H; Kikas, P; Pappas, C; Sfantou, D; Tziakas, D; Xanthopoulou, I; Ziakas, A | 1 |
| Bryant, JA; Bulluck, H; Chai, P; Chan, MHH; Chan, MY; Chawla, A; Chua, TS; Chung, YC; Fei, G; Hausenloy, DJ; Ho, AFW; Ho, HH; Hock, MOE; Hoe, AJ; Imran, SS; Lee, CH; Liew, BW; Lim, SH; Paradies, V; Roe, MT; Tan, JW; Teo, L; Watson, T; Wong, AS; Wong, E; Wong, PE; Yun, PLZ | 1 |
| Abtan, J; Bhatt, DL; Deliargyris, EN; Ducrocq, G; Elkin, S; Gibson, CM; Hamm, C; Harrington, RA; Mahaffey, KW; Menozzi, A; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Agarwal, M; Angiolillo, DJ; Bass, TA; Been, L; Briceno, M; Franchi, F; Kaufman, M; Nawaz, A; Pineda, AM; Rivas, A; Rollini, F; Shaikh, Z; Silva, G; Smairat, R; Soffer, D; Suryadevara, S; Wali, M; Zenni, MM | 1 |
| Erlinge, D; Grimfjärd, P; James, S; Lagerqvist, B; Varenhorst, C | 1 |
| Erlinge, D | 1 |
1 review(s) available for adenosine monophosphate and ST Elevation Myocardial Infarction
| Article | Year |
|---|---|
P2Y12 inhibitors for the treatment of acute coronary syndrome patients undergoing percutaneous coronary intervention: current understanding and outcomes.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Intravenous; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor | 2019 |
6 trial(s) available for adenosine monophosphate and ST Elevation Myocardial Infarction
| Article | Year |
|---|---|
Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and
Topics: Adenosine Monophosphate; Aged; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Tirofiban | 2021 |
Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarction.
Topics: Adenosine Monophosphate; Contrast Media; Gadolinium; Humans; Pancreatic Elastase; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2021 |
Cangrelor in Ticagrelor-Loaded STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Blood Platelets; Drug Therapy, Combination; Humans; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor | 2018 |
Platelet inhibition to target reperfusion injury trial: Rationale and study design.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Coronary Circulation; Double-Blind Method; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardial Reperfusion; Myocardial Reperfusion Injury; Myocardium; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Treatment Outcome; Ventricular Remodeling; Young Adult | 2019 |
Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial.
Topics: Adenosine Monophosphate; Aged; Double-Blind Method; Female; Heart Diseases; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; ST Elevation Myocardial Infarction; Thrombosis; Treatment Outcome | 2019 |
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Double-Blind Method; Drug Therapy, Combination; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
9 other study(ies) available for adenosine monophosphate and ST Elevation Myocardial Infarction
| Article | Year |
|---|---|
The Effects of Cangrelor on Platelet Aggregation in STEMI Patients: Methodological or Pharmacological Issues?
Topics: Adenosine Monophosphate; Humans; Platelet Aggregation; ST Elevation Myocardial Infarction; Treatment Outcome | 2022 |
Reply: The Effects of Cangrelor on Platelet Aggregation in STEMI Patients: Methodological or Pharmacological Issues?
Topics: Adenosine Monophosphate; Humans; Platelet Aggregation; ST Elevation Myocardial Infarction; Treatment Outcome | 2022 |
Intracoronary cangrelor administration-assisted primary percutaneous coronary intervention in a patient with essential thrombocythemia and recurrent ST-segment elevation myocardial infarction.
Topics: Adenosine Monophosphate; Adult; Angioplasty, Balloon, Coronary; Coronary Thrombosis; Drug-Eluting Stents; Humans; Hydroxyurea; Infusions, Intravenous; Male; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Recurrence; ST Elevation Myocardial Infarction; Thrombocythemia, Essential; Treatment Outcome | 2020 |
Discontinuation of both cangrelor and ticagrelor because of severe dyspnea during primary angioplasty.
Topics: Adenosine Monophosphate; Aged; Anxiety; Chest Pain; Coronary Angiography; Coronary Occlusion; Drug Substitution; Drug-Eluting Stents; Drug-Related Side Effects and Adverse Reactions; Dyspnea; Electrocardiography; Humans; Inferior Wall Myocardial Infarction; Male; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome; Withholding Treatment | 2021 |
Letter by Angiolillo et al Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial".
Topics: Adenosine Monophosphate; Humans; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Tirofiban | 2021 |
Response by Gargiulo et al to Letter Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial".
Topics: Adenosine Monophosphate; Humans; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Tirofiban | 2021 |
Cangrelor vs. glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Female; Gastrointestinal Hemorrhage; Hematocrit; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Retrospective Studies; ST Elevation Myocardial Infarction | 2021 |
Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
Topics: Adenosine Monophosphate; Aged; Coronary Thrombosis; Drug Utilization; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Sweden; Time Factors; Treatment Outcome | 2019 |
Cangrelor for ST-Segment-Elevation Myocardial Infarction.
Topics: Adenosine Monophosphate; Humans; Percutaneous Coronary Intervention; ST Elevation Myocardial Infarction; Ticagrelor | 2019 |